Wednesday, February 8, 2012
Amylin Pharmaceuticals Inc., of San Diego, reported 2011 non-GAAP operating income of $25.7 million, compared to a non-GAAP operating loss of $4.4 million in 2010. Total revenues for the 12 months ending Dec. 31, 2011, were $650.7 million. Net product sales of $621 .6 million included $517.7 million for Byetta (exenatide) and $103.9 million for Symlin (pramlintide acetate). In comparison, Amylin reported net product sales of $651.1 million in 2010, including $559.3 million for Byetta and $91.8 million for Symlin. Non-GAAP operating income for the quarter ending Dec. 31 was $17.6 million, compared to non-GAAP operating income of $22.9 million for the same period in 2010.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.